Abstract: Computed tomography (CT) perfusion is a novel imaging method to determine tumor perfusion using a low-dose CT technique to measure iodine concentration at multiple time points. We determined if early changes in perfusion differ between primary renal tumors and metastatic tumor sites in patients with renal cell carcinoma (RCC) receiving targeted anti-angiogenic therapy. A total of 10 patients with advanced RCC underwent a CT perfusion scan at treatment baseline and at one week after initiating treatment. Perfusion measurements included blood volume (BV), blood flow (BF), and flow extraction product (FEP) in a total of 13 lesions (six primary RCC tumors, seven RCC metastases). Changes between baseline and week 1 were compared between tumor locations: primary kidney tumors vs metastases. Metastatic lesions had a greater decrease in BF (average BF difference ± standard deviation (SD): −75.0 mL/100 mL/min ± 81) compared to primary kidney masses (−25.5 mL/100 mL/min ± 35). Metastatic tumors had a wider variation of change in BF, BV and FEP measures compared to primary renal tumors. Tumor diameters showed little change after one week, but early perfusion changes are evident, especially in metastatic lesions compared to primary lesions. Future studies are needed to determine if these changes can predict which patients are benefiting from targeted therapy.

Keywords: CT perfusion; renal cell carcinoma; metastases; targeted therapy; biomarker; therapeutic response
those who are not responding in order to allow them the opportunity to switch to a potentially more
effective therapy sooner.

Using CT perfusion, one can visualize and quantify blood perfusion in tissue \cite{15,16}. Low-dose contrast-enhanced CT images are obtained over multiple (25–30) time points during which an iodine-based contrast agent passes through the vasculature and tissue, allowing quantitative analysis of blood flow, blood volume, and mean transit time. CT perfusion is well established in stroke imaging but is a relatively new method of imaging abdominal tumors such as RCC. Due to its highly vascularized nature, renal cell carcinoma is especially amenable to visualization with CT perfusion \cite{17–22}. CT perfusion is not currently widely used in RCC because the standard accepted method of evaluating tumor response is to use size measurement and RECIST criteria. Since most RCC therapies are directed against angiogenesis, we hypothesize that tumor vascularity could decrease with successful treatment. Moreover, in RCC, targeted therapy can have a greater effect on metastatic sites than the renal primary tumor \cite{23}. Therefore, we compared early changes in vascularity in the primary tumor and metastatic sites. We selected an early 1-week time point to measure perfusion changes because targeted treatment reduces tumor vasculature, decreases proliferation, increases apoptosis and immune cell infiltration as early as 1–7 days after initiating treatment in preclinical and translational studies \cite{24–29}. We sought to describe early changes in perfusion and determine if there were any differences in perfusion between primary renal cell carcinoma tumors compared to metastatic lesions from RCC.

2. Results

Our analysis included 10 patients with advanced RCC who required treatment with anti-angiogenesis agents. Five patients had primary renal masses, one patient had both a primary renal mass and a metastatic lesion, and four patients had metastatic RCC lesions (in single or multiple sites, including adrenal, pancreas, lung, liver, and soft tissue). Patient demographics of tumor type and location, and administered treatment are shown in Table 1. A total of 13 lesions were analyzed: Six with primary renal masses and seven with metastases.

| Table 1. Patient Demographics, tumor type and location. |
|---------------------------------------------------------|
| **Mean Age** | 53.5 |
| **Gender** | 4F/6M |
| **Tumor Type** | clear cell |
| **Tumor Location** | 5 patients (pts) with primary renal masses |
| | | 4 pts with RCC metastasis (single or multiple) |
| | | 1 pt with primary RCC and 1 metastasis |
| **Treatment Type** | 2 axitinib |
| | | 2 sunitinib |
| | | 5 pazopanib |
| | | 1 sunitinib and gemcitabine |

At 12 weeks, four (67%) of the renal masses and two (29%) of the metastasized masses had stable RECIST measurements; two (33%) of the renal masses and five (71%) of the metastasized masses had RECIST measurements consistent with progressive disease. There was no statistically significant difference by tumor location for the difference in tumor size between the baseline and the eight-day scan (t-test p-value = 0.17), see Figure 1.
Figure 1. No significant change in tumor size by tumor location after eight days of treatment. Spaghetti plot of the maximum diameter (cm) of each tumor (primary renal mass: red; metastases: blue) at baseline and eight days after initiating treatment. Each line represents a single mass.

There was considerable variation in blood flow (BF), blood volume (BV) and flow extraction product (FEP) at each time point and in differences in BF, BV and FEP from baseline to the eight-day scan for both kidney and metastatic masses, see Figure 2 and Table 2. While metastatic masses showed a greater decrease in the average BF (BF difference (mean + SD): $-75.0 \pm 81$) than kidney masses ($-25.5 \pm 35$), there was no statistically significant difference in BF difference by tumor location (Wilcoxon rank sum test $p = 0.28$), see Figures 2 and 3.

Figure 2. Distribution of differences in computed tomography (CT) perfusion parameters by tumor location. (a) Changes between baseline and day eight in blood flow (BF). (b) Changes between baseline and day eight in blood volume (BV). (c) Changes between baseline and day eight in flow extraction product (FEP). BF, BV and FEP were measured with CT perfusion in patients with primary and metastatic renal cell carcinoma treated with an anti-angiogenic therapy.
**Table 2.** CT perfusion parameter values by tumor location.

| Parameter                  | Primary Renal Mass (n = 6) | Metastatic Mass (n = 7) |
|----------------------------|-----------------------------|-------------------------|
|                            | Baseline        | Day 8       | Difference       | Baseline        | Day 8       | Difference       |
| Blood volume               |                |             |                    |                |             |                    |
| Mean (SD)                  | 13.4 (8.20)    | 8.1 (5.61)  | −5.3 (3.25)       | 17.3 (9.4)     | 11.3 (8.60) | −6.1 (7.1)       |
| Median (IQR)               | 15.9 (6.0, 17.9)| 8.2 (3.0, 12.9)| −5.6 (−8.1, −3.0)| 15.6 (10.1, 27.8)| 7.7 (4.2, 18.2)| −3.2 (−11.9, −0.03)|
| Blood flow                 |                |             |                    |                |             |                    |
| Mean (SD)                  | 125.4 (70.5)   | 99.8 (73.0) | −25.5 (34.51)     | 235.7 (185.05) | 160.7 (159.70)| −75.0 (80.47)  |
| Median (IQR)               | 148.5 (64.0, 163.1)| 97.8 (37.3, 140.0)| −15.7 (−26.7, −3.8)| 148.4 (120.4, 352.3)| 94.2 (48.7, 233.6)| −99.7 (−118.7, −1.0)|
| Flow extraction product    |                |             |                    |                |             |                    |
| Mean (SD)                  | 60.6 (34.18)   | 39.9 (27.14) | −20.7 (17.91)     | 61.5 (28.70)   | 34.0 (24.43) | −27.5 (21.43)    |
| Median (IQR)               | 74.8 (31.4, 79.1)| 44.0 (13.0, 56.6)| −20.1 (−33.3, −2.09)| 61.6 (34.5, 79.8)| 28.6 (17.8, 64.7)| −40.1 (−42.5, 0.12)|

Blood volume (mL/100 mL), blood flow (mL/100 mL/min), flow extraction product (mL/100 mL/min); SD = standard deviation; IQR = interquartile range.

There was no statistically significant association between tumor location and clinical response (stable or progressive disease) (OR: 4.4 (90% CI: 0.43–60.54), \( p = 0.42 \)). Patients with stable disease had a greater decrease in BV difference for both kidney and metastatic masses compared to patients with progressive disease. Although not statistically significant, the magnitude of change was greater in metastatic masses compared to primary kidney masses, see Figure 4. Representative images of a primary renal lesion and metastatic lesions are shown, see Figures 5 and 6.
Figure 4. Blood volume and blood flow changes by clinical response and tumor location. (a) Differences in blood volume (BV) in primary renal lesions on day eight of treatment with tyrosine kinase inhibitor in patients who had either stable or progressive disease by RECIST 1.1 criteria at 12 weeks post-treatment. (b) Differences in blood volume (BV) in metastatic renal cell carcinoma lesions. (c) Differences in blood flow (BF) in primary renal lesions on day eight of treatment. (d) Differences in blood flow (BF) in metastatic lesions. Note that stable disease shows a larger decrease in BV in both primary kidney masses and metastatic disease compared to progressive disease and a greater decrease in BF is seen in stable metastatic disease compared to progressive disease.
Figure 5. Images of a primary renal lesion. (a) Axial contrast enhanced image and CT perfusion blood flow image before therapy of left renal mass (red arrows). Blood flow was measured to be 116 mL/100 mL/min and blood volume was 13.79 mL/100 mL. (b) An axial contrast enhanced image and CT perfusion image of same renal mass eight days after therapy shows a mild decrease in blood flow to 100.13 mL/100 mL/min and blood volume to 10.38 mL/100 mL, but with stable size of mass. Standard deviation (SD) for each measurement is shown on the table below the figure.
Figure 6. Images of a metastatic lesion. (a) Axial contrast enhanced image and CT perfusion images before therapy in patient with renal cell carcinoma metastases to the liver (red arrows). Blood flow is 83.3 mL/100 mL/min and blood volume is 7.08 mL/100 mL. (b) Axial contrast enhanced image and CT perfusion image of same patient eight days after therapy shows dramatic decrease in blood flow to 32.90 mL/100 mL/min and blood volume decrease to 3.35 mL/100 mL. Standard deviation (SD) for each measurement is shown on the table below the figure.

3. Discussion

Patients with advanced solid tumors rely upon tumor diameter measurements to determine response to treatment. Patients with RCC would benefit from imaging biomarkers that can determine the response to targeted therapy at an earlier time-point than 12 weeks; we selected patients treated with anti-angiogenesis agents as a tractable patient population for this initial study. We observed that early changes in BF and BV in advanced RCC patients were of greater magnitude in patients with stable disease compared to progressive disease. While we were unable to demonstrate statistical significance, our result is consistent with preclinical data in which successful anti-angiogenic treatment has been shown to inhibit VEGFR2, decrease tumor vessel number and density based on immunohistochemistry in xenograft and preclinical models [30–33]. In clinical studies of RCC, CT perfusion has been performed at five- and 10-week time points after initiating treatment, but we are the first to demonstrate that changes can be detected as early as eight days after treatment; however, whether early changes can reliably predict clinical outcome will need to be validated in a larger study. Nonetheless, we have demonstrated that measuring early changes in CT perfusion is possible.

For patients with advanced RCC, the goal of systemic treatment is to prevent overall tumor growth at all involved sites to reduce overall morbidity and mortality. In metastatic sites, tumor stabilization or shrinkage is required to reduce or prevent symptoms and preserve vital organ function.
For the primary kidney lesions, there is also an additional goal to control the lesion to prevent specific morbidity from pain or acute bleeding [34,35]. Therefore, we specifically evaluated the ability of CT perfusion acquisitions to measure changes in kidney lesions compared with distant metastases. Although we did not reach statistical significance, we found a larger decrease in BV in metastatic tumor sites compared to primary renal tumors in patients with stable disease. Our work suggests that early perfusion changes, especially in metastatic lesions, may help determine if patients are benefiting from targeted therapy. To our knowledge, no other study to date has examined the difference in response to treatment of primary RCC compared to metastatic disease using CT perfusion.

There were several limitations to our study. First, we included patients with advanced cancer (receiving up to four previous lines of therapy). Therefore, the best response in this population was “stable disease”, as no patient achieved significant tumor shrinkage at 12 weeks (i.e., we did not have any patients classified as a partial or complete response). We required that patients receive more than half the expected doses of chemotherapy; therefore, lack of tumor shrinkage was not due to compliance with taking medication but more likely due to the biology of the tumors. It is possible that patients who achieve a partial or complete response might have even greater decreases in vascularity measurements; however, we were not able to show this since we did not have patients who met this criterium. Lastly, this pilot study was a small cohort, intended to explore the possibility of observing changes in CT perfusion parameters. Larger studies in select patient populations will be needed to assess if vascularity measurements can be used for early therapeutic monitoring.

4. Materials and Methods

4.1. Study Protocol

The study was approved by the institutional review board at Stanford School of Medicine and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice. The study is listed on clinicaltrials.gov (identifier NCT01926990). All the patients provided written informed consent before study entry. In this prospective pilot study, patients were eligible if they had advanced RCC (stage 3 or 4), were scheduled to receive systemic treatment, had adequate renal function, and had no conflicting allergy. Generally, it is a standard of care to resect stage 3 or 4 tumors that are localized. The patients with localized tumors included in this study were referred by urologists for systemic therapy, either because the patient was too sick or physically unable to undergo surgery, or because the kidney lesion was too difficult to remove and systemic therapy was administered with the intent to shrink the tumor prior to surgery. Patients were excluded if pregnant. Within four weeks before starting systemic therapy, patients underwent a CT perfusion and a staging CT scan of the chest, abdomen and pelvis (baseline). Each patient subsequently received systemic treatment with an angiogenesis inhibitor (bevacizumab, pazopanib, sunitinib). After eight days (range 6–13 days) of treatment, a second CT perfusion acquisition was obtained. After a standard of care interval of approximately 90 days of treatment, a re-staging CT scan of the chest, abdomen and pelvis was performed for RECIST measurements to determine response to therapy.

4.2. CT Perfusion Technique

Each patient underwent a CT perfusion acquisition of either the primary renal mass (if present) or the largest metastatic tumor (≥2.0 cm) in the chest, abdomen, or pelvis. Each CT scan was performed on a SOMATOM Force CT scanner (Siemens Healthineers, Erlangen, Germany). In each scan, a low-dose, non-contrast CT scan was obtained through the region of interest to localize the tumor. CT perfusion images were acquired at 80 kV and 100 mAs using an adaptive 4D spiral mode with variable pitch and z-axis coverage of 114–224 mm, depending on the size of the area of interest around the tumor). Mean CTDIvol of 52.21 mGy (±18.8) and DLP of 992.68 mGy*cm (± 421.3) were utilized. Intravenous contrast (iohexol 370 or iohexol 300 if the patient had undergone a previous nephrectomy)
was administered through an antecubital vein at 5 cc/sec for a total of 50 cc followed by a 45 cc saline chaser at 5 cc/s. After a scan delay of 7 s, images were obtained every 1.5 s for 20 acquisitions, followed by every 3.0 s for another five acquisitions, resulting in a total acquisition time of 45 s. All patients were instructed to hold their breath as long as possible after inhalation. If they were unable to hold their breath for the entire scan duration, patients were instructed to take slow shallow breaths in order to minimize motion. Each examination was monitored by a radiologist with >10 years of experience in CT perfusion.

4.3. CT Perfusion Analysis

Each CT perfusion examination was post-processed and tumors were segmented on syngo.via VB10/VB20 (Siemens Healthineers, Erlangen, Germany) by two radiologists in consensus. Perfusion parameters were obtained using a deconvolution method following non-rigid body motion correction and 4D noise reduction. Arterial input function was obtained over the aorta or the largest artery near the tumor. Perfusion parameters included blood volume (BV), blood flow (BF), and flow extraction product (FEP). For perfusion analysis, 5 mm thick slices were used.

4.4. Treatment Response

The longest tumor dimension was measured in each lesion. Clinical response was defined as progressive disease, stable disease, partial response, or complete response based on RECIST 1.1 after 12 weeks of treatment. Progressive disease was defined as a ≥ 20% increase in the sum of target lesion diameters; stable disease was a < 30% decrease or a < 20% increase in the sum of target lesion diameters; partial response was defined as a ≥ 30% decrease in the sum of target lesion diameters; complete response was defined as disappearance of all lesions.

4.5. Analysis

We used descriptive statistics and graphical measures to assess if early changes in CT perfusion parameters (BF, BV, FEP) could be observed at day eight after the initiation of treatment. We used t-tests or Wilcoxon rank sum tests to compare the distribution of each CT perfusion parameter and tumor size by tumor location. Specifically, we compared the following measures by tumor location: Tumor size and individual perfusion parameters at baseline and at day eight as well as the difference in each measure from baseline to day eight. For patients with multiple lesions per organ, data from the largest lesion in the organ were used in our analysis. To evaluate the clinical response, we combined the treatment response categories into two groups: Stable or progressive disease and conducted univariable exact logistic regression to assess the association between clinical response and each individual measure for each tumor location separately (primary kidney mass or metastasis). Univariable exact logistic regression analysis was also used to determine the association of clinical response and tumor location. Significance testing was assessed at a two-sided alpha level of 0.10.

5. Conclusions

In conclusion, it is possible to perform one-week CT perfusion acquisitions in patients with RCC undergoing systemic treatment. We selected RCC as an optimal patient population to examine early changes in tumor perfusion due to the broad use of angiogenesis inhibitors for systemic therapy. There appear to be detectable changes in perfusion measurements in both primary and metastatic tumor sites as early as one week after initiating treatment. Future studies are planned to more fully evaluate the clinical potential for CT perfusion for early therapeutic monitoring.

Author Contributions: Author contributions are as follows: Conceptualization and methodology, A.C.F. and A.K. (Aya Kamaya); formal analysis, A.C.F., V.S., A.K. (Aya Kino), A.K. (Aya Kamaya); investigation A.C.F., A.K. (Aya Kamaya), A.K. (Aya Kino), T.J.M.; data curation, A.K. (Aya Kino); writing—original draft preparation, A.C.F., A.K. (Aya Kamaya); writing—review and editing, A.C.F., A.K. (Aya Kamaya), V.S., A.K. (Aya Kino), H.S., T.J.M.;
visualization, A.K. (Aya Kamaya); supervision, A.C.F., A.K. (Aya Kamaya); project administration T.J.M.; funding acquisition, A.C.F., A.K. (Aya Kamaya).

**Funding:** This research was funded by the Conquer Cancer Foundation (ACF) and Siemens Healthineers (AK). This work was partially supported by the Cancer Center Support Grant, P30CA124435. In particular, the research was facilitated by the Biostatistics Shared Resource.

**Acknowledgments:** This work is dedicated to the memory of Len Weinglass. We thank Christian Hoerner for his proofreading and suggestions.

**Conflicts of Interest:** Heiko Schmiedeskamp is an employee of Siemens Medical Solutions USA, Inc. Alice Fan is founder of Molecular Decisions, Inc. All other authors have no relevant disclosures. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Hsieh, J.J.; Mark, P.P.; Sabina, S.; Charles, S.; Laurence, A.; Manuela, S.; Daniel, Y.H.; James, L.; Vincenzo, F. Renal Cell Carcinoma. *Nat. Rev. Dis. Primers* **2017**, *3*, 17009. [CrossRef]

2. Posadas, E.M.; Suwicha, L.; Robert, A.F. Targeted Therapies for Renal Cell Carcinoma. *Nat. Rev. Nephrol.* **2017**, *13*, 496–511. [CrossRef] [PubMed]

3. McKay, R.R.; Dominick, B.; Toni, K.C. Evolving Systemic Treatment Landscape for Patients with Advanced Renal Cell Carcinoma. *J. Clin. Oncol.* **2018**, *36*, 3615–3623. [CrossRef]

4. Motzer, R.J.; Thomas, E.H.; Piotr, T.M.; Dror, M.B.; Olivier, R.; Stéphane, O.; Sylvie, N.; Cezary, S.; Sindy, T.K.; et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. *N. Engl. J. Med.* **2007**, *356*, 115–124. [CrossRef]

5. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2007**, *356*, 2271–2281. [CrossRef] [PubMed]

6. Motzer, R.J.; Hutson, T.E.; Glen, H.; Michaelson, M.D.; Molina, A.; Eisen, T.; Jassem, J.; Zolnierek, J.; Maroto, J.P.; Mellado, B.; et al. Lenvatinib, Everolimus, and the Combination in Patients with Metastatic Renal Cell Carcinoma: A Randomised, Phase 2, Open-Label, Multicentre Trial. *Lancet Oncol.* **2015**, *16*, 1473–1482. [CrossRef]

7. Escudier, B.; Joaquim, B.; Sylvie, N.; Emilio, B.; Bohuslav, M.; Sergio, B.; Alain, R.; Sophie, G.; Sangeeta, J.; Vesna, S. Phase III Trial of Bevacizumab plus Interferon Alfa-2a in Patients with Metastatic Renal-Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. *J. Clin. Oncol.* **2010**, *28*, 2144–2150. [CrossRef] [PubMed]

8. Motzer, R.J.; Nizar, M.; Tannir, D.F.; McDermott, O.; Aréin, F.; Bohuslav, M.; Toni, K.C.; Elizabeth, R.P.; Philippe, B.; Camillo, P.; et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2018**, *378*, 1277–1289. [CrossRef] [PubMed]

9. Choueiri, T.K.; Susan, H.; Ben, L.S.; Olwen, H.M.; Dror, M.; Meigara, K.W.; Darren, R.F.; Olencki, T.; Picus, J.; Small, E.J.; et al. Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. *J. Clin. Oncol.* **2017**, *35*, 591–597. [CrossRef] [PubMed]

10. Sternberg, C.N.; Ian, D.D.; JozeF, M.; Cezary, S.; Eunsik, L.; John, W.; Carlos, H.B.; Salman, P.; Gladkov, O.A.; Kavina, A.; et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. *J. Clin. Oncol.* **2010**, *28*, 1061–1068. [CrossRef]

11. Rini, B.I.; Elizabeth, R.P.; Viktor, S.; Rustem, G.; Robert, H.; Dmitry, N.; Frédéric, P.; Boris, A.; Denis, S.; Bohuslav, M.; et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2019**, *380*, 1116–1127. [CrossRef] [PubMed]

12. Motzer, R.J.; Konstantin, P.; John, H.; Brian, R.; Laurence, A.; Matthew, T.C.; Balaji, V.; Christian, K.; Sylvie, N.; Motohide, U.; et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2019**, *380*, 1103–1115. [CrossRef] [PubMed]

13. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (version 1.1). *Eur. J. Cancer* **2009**, *45*, 228–247. [CrossRef] [PubMed]
14. Chen, V.; Cynthia, G.; Chiyuan, A.; Zhang, S.S.; Howard, E.L.; Alice, C.F. Economic Burden of Empiric Drug Utilization in Metastatic Renal Cell Carcinoma Emphasizes the Need for Early Biomarkers of Response. *JCO* 2017, 35, e16072. [CrossRef]

15. Prezzi, D.; Aisha, K.; Vicky, G. Perfusion CT Imaging of Treatment Response in Oncology. *Eur. J. Radiol.* 2015, 12, 2380–2385. [CrossRef] [PubMed]

16. Fournier, L.S.; Stephane, O.; Rokhaya, T.; Ludovic, T.; Eugeniou, B.; Jacques, M.; Daniel, B.; Gilles, C.; Guy, F.; Charles, A.C. Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-Enhanced CT. *Radiology* 2010, 256, 511–518. [CrossRef] [PubMed]

17. Brufau, B.P.; Carmen, S.C.; Laura, B.V.; Rafael, S.I.; Begoña, M.G.; Carlos, N.M. Metastatic Renal Cell Carcinoma: Radiologic Findings and Assessment of Response to Targeted Antiangiogenic Therapy by Using Multidetector CT. *Radiographics* 2013, 33, 1691–1716. [CrossRef]

18. Chen, Y.; Zhang, J.; Dai, J.; Feng, X.; Lu, H.; Zhou, C. Angiogenesis of Renal Cell Carcinoma: Perfusion CT Findings. *Abdom. Imaging* 2010, 35, 622–628. [CrossRef]

19. Reiner, C.S.; Goetti, R.; Eberli, D.; Boss, A.; Pfammatter, T.; Moch, H.; Sulser, T.; Alkadhi, H. CT Perfusion of Renal Cell Carcinoma: Impact of Volume Coverage on Quantitative Analysis. *Invest. Radiol.* 2012, 47, 33–40. [CrossRef]

20. Ng, C.S.; Xiaohong, W.; Silvana, C.F.; Lin, E.; Chusilp, C.; Nizar, M.T. Perfusion CT in Patients with Metastatic Renal Cell Carcinoma Treated with Interferon. *AJR* 2010, 194, 166–171. [CrossRef]

21. Reiner, C.S.; Matthias, R.; Thore, T.; Daniel, E.; Ernst, K.; Thomas, F.; Tullio, S.; Holger, M.; Hatem, A. Computed Tomography Perfusion Imaging of Renal Cell Carcinoma: Systematic Comparison with Histopathological Angiogenic and Prognostic Markers. *Invest. Radiol.* 2013, 48, 183–191. [CrossRef]

22. Kaneoya, K.; Ueda, T.; Suito, H.; Nanazawa, Y.; Tamaru, J.; Isobe, K.; Naya, Y.; Tobe, T.; Motoori, K.; Yamamoto, S.; et al. Functional Computed Tomography Imaging of Tumor-Induced Angiogenesis: Preliminary Results of New Tracer Kinetic Modeling Using a Computer Discretization Approach. *Radiat. Med.* 2008, 26, 213–221. [CrossRef]

23. Joachim, D.; Inga, H.; Harald, H.; Christine, W.; Helmut, M.; Marianne, M.; Jeanette, W.; Georg, M.-B.; Clemens, U.; Dieter, M. Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model. *Cancer Res.* 2000, 60, 4819–4824.

24. Patnaik, A.; Swanson, K.D.; Csizmadia, E.; Solanki, A.; Landon-Brace, N.; Gehring, M.P.; Helenius, K.; Olson, B.M.; Pyzer, A.R.; Wang, L.C.; et al. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. *Cancer Discov.* 2017, 7, 750–765. [CrossRef]

25. Huang, D.; Ding, Y.; Li, Y.; Luo, W.M.; Zhang, Z.F.; Snider, J.; Vandenbeldt, K.; The, B.T. Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma. *Cancer Res.* 2010, 70, 1053–1062. [CrossRef]

26. Batchelor, T.T.; Sorensen, A.G.; di Tomaso, E.; Zhang, W.T.; Duda, D.G.; Cohen, K.S.; ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. *Cancer Cell* 2007, 11, 83–95. [CrossRef]

27. Morgan, B.; Thomas, A.L.; Drevs, J.; Hennig, J.; Buchert, M.; Jivan, A.; Horsfield, M.A.; Mross, K.; Ball, H.A.; Lee, L.; et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients with Advanced Colorectal Cancer and Liver Metastases: Results from Two Phase I Studies. *J. Clin. Oncol.* 2003, 21, 3955–3964.

28. Laird, A.D.; Christensen, J.G.; Li, G.; Carver, J.; Smith, K.; Xin, X.; Moss, K.G.; Louie, S.G.; Mendel, D.B.; Cherrington, J.M. SU6668 Inhibits Flik-1/KDR and PDGFRbeta in Vivo, Resulting in Rapid Apoptosis of Tumor Vasculature and Tumor Regression in Mice. *FASEB J.* 2002, 16, 681–690. [CrossRef]

29. Christiane, J.B.; Wenbiao, L.; Darren, W.D.; Raymond, M.S.; David, J.M.; Michael, R.W.; Corazon, D.B.; Daniel, J.H.; Lee, M.E. Vascular Endothelial Growth Factor Is an in Vivo Survival Factor for Tumor Endothelium in a Murine Model of Colorectal Carcinoma Liver Metastases. *Cancer* 2000, 89, 488–499.

30. Nielsen, T.K.; Østraat, Ø.; Graumann, O.; Pedersen, B.G.; Andersen, G.; Hoyer, S.; Borre, M. Computed Tomography Perfusion, Magnetic Resonance Imaging, and Histopathological Findings After Laparoscopic Renal Cryoaablation: An In Vivo Pig Model. *Technol. Cancer Res. Treat.* 2017, 16, 406–413. [CrossRef]
31. Luna, A.; Vilanova, J.C.; Da Cruz, L.C.H., Jr.; Rossi, S.E. (Eds.) *Functional Imaging in Oncology: Clinical Applications*; Springer: Berlin, Germany, 2014.

32. Mains, J.R.; Donskov, F.; Pedersen, E.M.; Madsen, H.H.T.; Thygesen, J.; Thorup, K.; Rasmussen, F. Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients. *Br. J. Radiol.* 2018, 91, 20160795. [CrossRef]

33. Hellbach, K.; Sterzik, A.; Sommer, W.; Karpitschka, M.; Hummel, N.; Casuscelli, J.; Ingrisch, M.; Schlemmer, M.; Graser, A.; Staehler, M. Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. *Eur. Radiol.* 2017, 27, 2532–2537. [CrossRef]

34. Choueiri, T.K.; Xie, W.; Kollmannsberger, C.; North, S.; Knox, J.J.; Lampard, J.G.; McDermott, D.F.; Rini, B.I.; Heng, D.Y. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. *J. Urol.* 2011, 185, 60–66. [CrossRef]

35. Méjean, A.; Ravaud, A.; Thezenas, S.; Colas, S.; Beauval, J.-B.; Bensalah, K.; Lionnel, G.; Antoine, T.-V.; Luc, C.; Hervé, L. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. *N. Engl. J. Med.* 2018, 379, 417–427. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).